| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Hamon Center for Therapeutic Oncology Research [R. M., S. T., K. O. T., K. H., A. K. V., S. Z-M., A. J. F., J. D. M., A. F. G.], and Departments of Pathology [A. K. V., A. F. G.], Internal Medicine [J. D. M.], Pharmacology [J. D. M.], and Urology [A. S.], University of Texas Southwestern Medical Center, Dallas, Texas 75390-8593, and Department of Pathology, University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030 [F. V-L., B. C.]
We investigated the aberrant promoter methylation profile of bladder cancers and correlated the data with clinicopathological findings. The methylation status of 10 genes was determined in 98 surgically resected bladder cancers, and we calculated the median methylation index (MI), a reflection of the methylated fraction of the genes tested. Methylation frequencies of the genes tested in bladder cancers were 36% for CDH1, 35% for RASSF1A and APC, 29% for CDH13, 16% for FHIT, 15% for RARß, 11% for GSTP1, 7% for p16INK4A, 4% for DAPK, and 2% for MGMT. Methylation of four of the individual genes (CDH1, RASSF1A, APC, and CDH13) and the MI were significantly correlated with several parameters of poor prognosis (tumor grade, growth pattern, muscle invasion, tumor stage, and ploidy pattern). Methylation of CDH1, FHIT, and a high MI were associated with shortened survival. CDH1 methylation positive status was independently associated with poor survival in multivariate analyses. Our results suggest that the methylation profile may be a potential new biomarker of risk prediction in bladder cancer.
This article has been cited by other articles:
|
|
 |
|
  M. Brait, S. Begum, A. L. Carvalho, S. Dasgupta, A. L. Vettore, B. Czerniak, O. L. Caballero, W. H. Westra, D. Sidransky, and M. O. Hoque Aberrant Promoter Methylation of Multiple Genes during Pathogenesis of Bladder Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2008; 17(10): 2786 - 2794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Marsit, E. A. Houseman, A. R. Schned, M. R. Karagas, and K. T. Kelsey Promoter hypermethylation is associated with current smoking, age, gender and survival in bladder cancer Carcinogenesis, August 1, 2007; 28(8): 1745 - 1751. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Yates, I. Rehman, M. F. Abbod, M. Meuth, S. S. Cross, D. A. Linkens, F. C. Hamdy, and J. W.F. Catto Promoter Hypermethylation Identifies Progression Risk in Bladder Cancer Clin. Cancer Res., April 1, 2007; 13(7): 2046 - 2053. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zhang, Z. Li, Y. Cheng, F. Jia, R. Li, M. Wu, K. Li, and L. Wei CpG Island Methylator Phenotype Association with Elevated Serum {alpha}-Fetoprotein Level in Hepatocellular Carcinoma Clin. Cancer Res., February 1, 2007; 13(3): 944 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Gu, D. Berman, C. Lu, I. I. Wistuba, J. A. Roth, M. Frazier, M. R. Spitz, and X. Wu Aberrant Promoter Methylation Profile and Association with Survival in Patients with Non-Small Cell Lung Cancer Clin. Cancer Res., December 15, 2006; 12(24): 7329 - 7338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Mitra, R. H. Datar, and R. J. Cote Molecular Pathways in Invasive Bladder Cancer: New Insights Into Mechanisms, Progression, and Target Identification J. Clin. Oncol., December 10, 2006; 24(35): 5552 - 5564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. O. Hoque, S. Begum, O. Topaloglu, A. Chatterjee, E. Rosenbaum, W. Van Criekinge, W. H. Westra, M. Schoenberg, M. Zahurak, S. N. Goodman, et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst, July 19, 2006; 98(14): 996 - 1004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Knowles Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis, March 1, 2006; 27(3): 361 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Brena, H. Auer, K. Kornacker, B. Hackanson, A. Raval, J. C. Byrd, and C. Plass Accurate quantification of DNA methylation using combined bisulfite restriction analysis coupled with the Agilent 2100 Bioanalyzer platform Nucleic Acids Res., February 7, 2006; 34(3): e17 - e17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Marsit, M. R. Karagas, H. Danaee, M. Liu, A. Andrew, A. Schned, H. H. Nelson, and K. T. Kelsey Carcinogen exposure and gene promoter hypermethylation in bladder cancer Carcinogenesis, January 1, 2006; 27(1): 112 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-J. Kim, E.-J. Kim, P. Jeong, C. Quan, J. Kim, Q.-L. Li, J.-O. Yang, Y. Ito, and S.-C. Bae RUNX3 Inactivation by Point Mutations and Aberrant DNA Methylation in Bladder Tumors Cancer Res., October 15, 2005; 65(20): 9347 - 9354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. van der Weyden, K. K. Tachibana, M. A. Gonzalez, D. J. Adams, B. L. Ng, R. Petty, A. R. Venkitaraman, M. J. Arends, and A. Bradley The RASSF1A Isoform of RASSF1 Promotes Microtubule Stability and Suppresses Tumorigenesis Mol. Cell. Biol., September 15, 2005; 25(18): 8356 - 8367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Makarla, M. H. Saboorian, R. Ashfaq, K. O. Toyooka, S. Toyooka, J. D. Minna, A. F. Gazdar, and J. O. Schorge Promoter Hypermethylation Profile of Ovarian Epithelial Neoplasms Clin. Cancer Res., August 1, 2005; 11(15): 5365 - 5369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Agathanggelou, W. N. Cooper, and F. Latif Role of the Ras-Association Domain Family 1 Tumor Suppressor Gene in Human Cancers Cancer Res., May 1, 2005; 65(9): 3497 - 3508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W.F. Catto, A.-R. Azzouzi, I. Rehman, K. M. Feeley, S. S. Cross, N. Amira, G. Fromont, M. Sibony, O. Cussenot, M. Meuth, et al. Promoter Hypermethylation Is Associated With Tumor Location, Stage, and Subsequent Progression in Transitional Cell Carcinoma J. Clin. Oncol., May 1, 2005; 23(13): 2903 - 2910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tommasi, R. Dammann, Z. Zhang, Y. Wang, L. Liu, W. M. Tsark, S. P. Wilczynski, J. Li, M. You, and G. P. Pfeifer Tumor Susceptibility of Rassf1a Knockout Mice Cancer Res., January 1, 2005; 65(1): 92 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Clement, F. T. Bosman, C. Fontolliet, and J. Benhattar Monoallelic Methylation of the APC Promoter Is Altered in Normal Gastric Mucosa Associated with Neoplastic Lesions Cancer Res., October 1, 2004; 64(19): 6867 - 6873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Dulaimi, I. I. de Caceres, R. G. Uzzo, T. Al-Saleem, R. E. Greenberg, T. J. Polascik, J. S. Babb, W. E. Grizzle, and P. Cairns Promoter Hypermethylation Profile of Kidney Cancer Clin. Cancer Res., June 15, 2004; 10(12): 3972 - 3979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Boorjian, S. K. Tickoo, N. P. Mongan, H. Yu, D. Bok, R. R. Rando, D. M. Nanus, D. S. Scherr, and L. J. Gudas Reduced Lecithin: Retinol Acyltransferase Expression Correlates with Increased Pathologic Tumor Stage in Bladder Cancer Clin. Cancer Res., May 15, 2004; 10(10): 3429 - 3437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Takahashi, N. Shivapurkar, J. Reddy, H. Shigematsu, K. Miyajima, M. Suzuki, S. Toyooka, S. Zochbauer-Muller, J. Drach, G. Parikh, et al. DNA Methylation Profiles of Lymphoid and Hematopoietic Malignancies Clin. Cancer Res., May 1, 2004; 10(9): 2928 - 2935. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yegnasubramanian, J. Kowalski, M. L. Gonzalgo, M. Zahurak, S. Piantadosi, P. C. Walsh, G. S. Bova, A. M. De Marzo, W. B. Isaacs, and W. G. Nelson Hypermethylation of CpG Islands in Primary and Metastatic Human Prostate Cancer Cancer Res., March 15, 2004; 64(6): 1975 - 1986. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Zheng, X. Ma, L. Zhang, L. Gunn, M. T. Smith, J. L. Wiemels, K. Leung, P. A. Buffler, and J. K. Wiencke Hypermethylation of the 5' CpG Island of the FHIT Gene Is Associated with Hyperdiploid and Translocation-Negative Subtypes of Pediatric Leukemia Cancer Res., March 15, 2004; 64(6): 2000 - 2006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Dulaimi, R. G. Uzzo, R. E. Greenberg, T. Al-Saleem, and P. Cairns Detection of Bladder Cancer in Urine by a Tumor Suppressor Gene Hypermethylation Panel Clin. Cancer Res., March 15, 2004; 10(6): 1887 - 1893. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. G. Sathyanarayana, R. Maruyama, A. Padar, M. Suzuki, J. Bondaruk, A. Sagalowsky, J. D. Minna, E. P. Frenkel, H. B. Grossman, B. Czerniak, et al. Molecular Detection of Noninvasive and Invasive Bladder Tumor Tissues and Exfoliated Cells by Aberrant Promoter Methylation of Laminin-5 Encoding Genes Cancer Res., February 15, 2004; 64(4): 1425 - 1430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. H. N. Wong, J. Chan, J. Wong, and P. K. H. Tam Ubiquitous Aberrant RASSF1A Promoter Methylation in Childhood Neoplasia1 Clin. Cancer Res., February 1, 2004; 10(3): 994 - 1002. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ishii, A. Vecchione, Y. Furukawa, K. Sutheesophon, S.-Y. Han, T. Druck, T. Kuroki, F. Trapasso, M. Nishimura, Y. Saito, et al. Expression of FRA16D/WWOX and FRA3B/FHIT Genes in Hematopoietic Malignancies Mol. Cancer Res., November 1, 2003; 1(13): 940 - 947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. J. Issa Methylation and Prognosis: Of Molecular Clocks and Hypermethylator Phenotypes Clin. Cancer Res., August 1, 2003; 9(8): 2879 - 2881. [Full Text] [PDF]
|
|
|
|
|
|
M. V. Brock, M. Gou, Y. Akiyama, A. Muller, T.-T. Wu, E. Montgomery, M. Deasel, P. Germonpre, L. Rubinson, R. F. Heitmiller, et al. Prognostic Importance of Promoter Hypermethylation of Multiple Genes in Esophageal Adenocarcinoma Clin. Cancer Res., August 1, 2003; 9(8): 2912 - 2919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Whitcomb, D. G. Mutch, T. J. Herzog, J. S. Rader, R. K. Gibb, and P. J. Goodfellow Frequent HOXA11 and THBS2 Promoter Methylation, and a Methylator Phenotype in Endometrial Adenocarcinoma Clin. Cancer Res., June 1, 2003; 9(6): 2277 - 2287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Spugnardi, S. Tommasi, R. Dammann, G. P. Pfeifer, and D. S. B. Hoon Epigenetic Inactivation of RAS Association Domain Family Protein 1 (RASSF1A) in Malignant Cutaneous Melanoma Cancer Res., April 1, 2003; 63(7): 1639 - 1643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kuroki, F. Trapasso, S. Yendamuri, A. Matsuyama, H. Alder, M. Mori, and C. M. Croce Promoter Hypermethylation of RASSF1A in Esophageal Squamous Cell Carcinoma Clin. Cancer Res., April 1, 2003; 9(4): 1441 - 1445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Toyooka, K. O. Toyooka, K. Harada, K. Miyajima, P. Makarla, U. G. Sathyanarayana, J. Yin, F. Sato, N. Shivapurkar, S. J. Meltzer, et al. Aberrant Methylation of the CDH13 (H-cadherin) Promoter Region in Colorectal Cancers and Adenomas Cancer Res., June 1, 2002; 62(12): 3382 - 3386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Kuzmin, J. W. Gillespie, A. Protopopov, L. Geil, K. Dreijerink, Y. Yang, C. D. Vocke, F.-M. Duh, E. Zabarovsky, J. D. Minna, et al. The RASSF1A Tumor Suppressor Gene Is Inactivated in Prostate Tumors and Suppresses Growth of Prostate Carcinoma Cells Cancer Res., June 1, 2002; 62(12): 3498 - 3502. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
